PMID- 25874530
OWN - NLM
STAT- MEDLINE
DCOM- 20160309
LR  - 20221207
IS  - 1399-5618 (Electronic)
IS  - 1398-5647 (Linking)
VI  - 17
IP  - 5
DP  - 2015 Aug
TI  - The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated 
      with increased body mass index and insulin resistance measures in bipolar 
      disorder and schizophrenia.
PG  - 528-35
LID - 10.1111/bdi.12294 [doi]
AB  - OBJECTIVES: We tested the hypothesis that a common functional variant in 
      brain-derived neurotrophic factor (BDNF), Val66Met, which has been shown to be 
      associated with increased body mass index (BMI) in schizophrenia (SCZ) and 
      schizoaffective disorder (SAD), is also associated with antipsychotic-induced 
      weight gain in bipolar disorder (BPD). Association of Val66Met with other 
      metabolic measures, including high- and low-density cholesterol, triglycerides, 
      total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested. 
      METHODS: This was a 12-month, prospective, randomized trial of two atypical 
      antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk 
      to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or 
      SAD (n = 76). RESULTS: BMI was significantly greater in all diagnoses for Met66 
      allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a 
      greater increase in the triglycerides/high-density (HDL) cholesterol ratio 
      (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, 
      and log-triglycerides (p = 0.04), after three or six months of treatment. Met66 
      carriers had the greatest increase in log-triglycerides (p = 0.03) and 
      triglycerides/HDL cholesterol ratio after three months of treatment with 
      risperidone (p = 0.003), and the highest BMI at six months (p = 0.01). 
      CONCLUSIONS: The positive association of BNDF Val66Met with high BMI values 
      replicates previous findings in patients with SCZ and indicates the BDNF Val66Met 
      genotype as a potential risk factor for obesity and insulin resistance measures 
      in patients with BPD receiving antipsychotics as well.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bonaccorso, Stefania
AU  - Bonaccorso S
AD  - Department of Psychosis Studies, Institute of Psychiatry at the Maudsley, King's 
      College London, London, UK.
FAU - Sodhi, Monsheel
AU  - Sodhi M
AD  - Department of Pharmacy Practice, University of Illinois, Chicago, IL, USA.
FAU - Li, Jiang
AU  - Li J
AD  - Department of Psychiatry and Behavioural Sciences, Northwestern University, 
      Chicago, IL, USA.
FAU - Bobo, William V
AU  - Bobo WV
AD  - Mayo Clinic, Rochester, MN, USA.
FAU - Chen, Yuejin
AU  - Chen Y
AD  - Southern Arizona VA Health Care System, Tucson, AZ, USA.
FAU - Tumuklu, Mevhibe
AU  - Tumuklu M
AD  - Faculty of Medicine, Department of Psychiatry, Gaziosmanpasa University, Tokat, 
      Turkey.
FAU - Theleritis, Christos
AU  - Theleritis C
AD  - Department of Psychosis Studies, Institute of Psychiatry at the Maudsley, King's 
      College London, London, UK.
FAU - Jayathilake, Karuna
AU  - Jayathilake K
AD  - Department of Psychiatry and Behavioural Sciences, Northwestern University, 
      Chicago, IL, USA.
FAU - Meltzer, Herbert Y
AU  - Meltzer HY
AD  - Department of Psychiatry and Behavioural Sciences, Northwestern University, 
      Chicago, IL, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150415
PL  - Denmark
TA  - Bipolar Disord
JT  - Bipolar disorders
JID - 100883596
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antipsychotic Agents/*adverse effects
MH  - Benzodiazepines/adverse effects
MH  - Bipolar Disorder/*drug therapy
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cholesterol, HDL/metabolism
MH  - Cholesterol, LDL/metabolism
MH  - Dyslipidemias/chemically induced/genetics/metabolism
MH  - Female
MH  - Genotype
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Insulin Resistance/*genetics
MH  - Male
MH  - Middle Aged
MH  - Obesity/chemically induced/*genetics/metabolism
MH  - Olanzapine
MH  - Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - Psychotic Disorders/*drug therapy
MH  - Risk Factors
MH  - Risperidone/adverse effects
MH  - Schizophrenia/*drug therapy
MH  - Triglycerides/metabolism
OTO - NOTNLM
OT  - antipsychotic drugs
OT  - bipolar disorder
OT  - body mass index
OT  - brain-derived neurotrophic factor (BDNF) Val66Met
OT  - glucose
OT  - lipids
OT  - schizophrenia
EDAT- 2015/04/16 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/04/07 00:00 [received]
PHST- 2014/12/17 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/03/10 06:00 [medline]
AID - 10.1111/bdi.12294 [doi]
PST - ppublish
SO  - Bipolar Disord. 2015 Aug;17(5):528-35. doi: 10.1111/bdi.12294. Epub 2015 Apr 15.